Is BPC-157 Legal in 2026? FDA PCAC Vote, 503A Compounding Rules & What Buyers Need to Know

BPC-157 is still an unapproved drug in the United States in August 2026. The FDA Pharmacy Compounding Advisory Committee (PCAC) recommended 8 yes, 6 no, 1 abstention to add BPC-157 to the Section 503A bulks list on July 23 2026, but that non-binding vote does not change the law until FDA completes formal rulemaking. Doctors may prescribe or pharmacies may compound BPC-157 only if they meet every 503A patient-specific requirement and their state board of pharmacy allows it. Until the final rule is published, marketing the peptide remains subject to FDA enforcement.

• The PCAC vote on BPC-157 (free base and acetate) was 8 yes, 6 no, 1 abstention out of 15 members on July 23 2026. (statnews.com)
• PCAC recommendations do not become law; FDA must issue a notice-and-comment rule, a process that historically takes 12 to 18 months. (fda.gov)
• BPC-157 is not on the current 503A bulks list, so compounded prescriptions remain “ineligible” unless FDA exercises enforcement discretion case-by-case. (fda.gov)
• At least nine states, including California and New York, restrict pharmacies from compounding non-monograph peptides for out-of-state patients. (pharmacy.ca.gov)
• FDA issued multiple warning letters citing BPC-157 between 2019 and 2024, and the substance appears on the agency’s safety-risk list. (fda.gov)

What BPC-157 Is and Why People Use It

BPC-157 is a 15-amino-acid fragment of a naturally occurring gastric protein that early animal studies suggest may accelerate tissue repair and reduce gastrointestinal inflammation. It has never undergone FDA-approved human trials for safety or efficacy, and no U.S. manufacturer holds a New Drug Application for the peptide. Interest surged after small investigator-initiated studies overseas linked the compound to reduced ulcerative-colitis symptoms and faster tendon healing. Our human-study tracker summarizes every peer-reviewed trial to date.

Definition (60 words): BPC-157 is an experimental synthetic peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that is sold for “research” but investigated off-label for gut, tendon, and nerve repair. The molecule is not FDA approved, not listed in the United States Pharmacopeia, and currently classed by FDA as an unapproved drug substance. (fda.gov)

Is BPC-157 Legal in the United States in 2026?

The short answer: BPC-157 is not illegal to possess, but it is illegal to market, distribute, or compound for human use unless you meet every condition of Section 503A and relevant state law. Because BPC-157 lacks an approved NDA and is not on the 503A bulks list, pharmacies that compound it without specific FDA enforcement discretion risk warning letters or product seizure. Physicians who prescribe it must write patient-specific scripts that are compounded by a state-licensed pharmacy under the practice-of-medicine exemption, yet many boards of pharmacy view such scripts as impermissible until FDA finalizes the bulks list.

What Happened at the July 2026 PCAC Meeting?

On July 23 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8-6 (with one abstention) to recommend adding BPC-157 to the 503A bulks list for treatment of ulcerative colitis. The same margin applied to the acetate salt form.

Vote context: FDA staff had advised against inclusion, citing limited human safety data, but public testimony from gastroenterologists and patient advocates swayed several members. STAT News described “an audible gasp” in the room when the tally was announced. (statnews.com)

Why the vote does not equal approval: PCAC recommendations are advisory. FDA must publish a proposed rule in the Federal Register, collect public comments, and then issue a final rule before any peptide is officially “on the list.” The agency took 14 months on average to finalize the first six substances in 2019. (fda.gov)

How 503A Eligibility Determines Compounding Rights

Section 503A of the Food, Drug, and Cosmetic Act carves out limited exemptions from FDA approval, labeling, and Good Manufacturing Practices for patient-specific compounded drugs. To qualify, a pharmacist or physician must:

• Compound only after receiving a valid prescription for an identified individual patient.
• Use a bulk drug substance that either has a USP/NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list. (fda.gov)
• Follow USP <795> or <797> standards for non-sterile or sterile preparations.
• Not distribute more than 5 percent of total compounded prescriptions out of state unless the state has signed the FDA–NABP Memorandum of Understanding.

BPC-157 fails the second prong today, so any pharmacy that compounds it is out of compliance unless FDA decides not to enforce. Several warning letters have cited this exact violation. (fda.gov)

State-by-State Prescribing and Shipping Realities

Even after FDA rulemaking, state boards of pharmacy control licensing and discipline. As of August 2026, at least nine states require pharmacists to verify that every compounded sterile injectable contains an ingredient recognized by USP or FDA. California’s November 2025 policy statement specifically flags experimental peptides as “high-risk APIs” that may not be shipped into the state without explicit board approval. (pharmacy.ca.gov)

How shipping restrictions work: A Texas-licensed 503A pharmacy can legally fill a BPC-157 prescription for a Texas patient, but if it mails the same drug to a California address, it violates both California sterile-compounding rules and the FDA–NABP MOU 5 percent cap.

Before writing or filling a prescription, clinicians should consult their state board and the peptide regulations guide for a current map of restrictions.

FDA Warning-Letter and Enforcement Landscape

Since 2019, FDA has issued at least four publicly available warning letters that cite BPC-157 as an ineligible bulk substance. Examples include:

• Tailor Made Compounding (April 1 2020) - cited for using BPC-157 and 18 other peptides not on the bulks list. (fda.gov)
• Prescription Dispensing Laboratories (July 30 2019) - cited for compounding BPC-157 acetate without patient-specific documentation. (fda.gov)
• Predator Nutrition (October 23 2020) - cited for marketing a BPC-157 oral supplement as a COVID-19 therapy. (fda.gov)

Placement on FDA’s Safety-Risk List: In May 2026 the agency added BPC-157 to its “bulk drug substances that may present significant safety risks” list, highlighting immunogenicity and potential reproductive toxicity. (fda.gov) This designation signals heightened scrutiny until more human data emerge.

Practical Next Steps for Patients and Clinicians

Confirm state rules first. Call your state board of pharmacy or check its posted compounding policies for non-USP peptides.

Use documented informed consent. Explain that BPC-157 is investigational, unapproved, and its legal status could change after FDA rulemaking.

Source from inspected pharmacies. If you proceed, choose a 503A pharmacy accredited by NABP or your state’s sterile-compounding program, and ask for third-party potency and sterility certificates.

Monitor FDA dockets. Subscribe to Federal Register notices for Docket No. FDA-2016-N-3464, where the agency posts proposed bulks-list rules.

For dosing considerations, see our BPC-157 dosage guide. For broader context on physician-ordered peptides, read the guide to peptide prescriptions.